CJC-1295 (With DAC): Long-Acting GHRH Analogue Research

CJC-1295 with DAC is a GHRH analogue incorporating a Drug Affinity Complex (DAC), a reactive maleimidopropionic acid (MPA) group that forms a covalent thioether bond with Cys-34 of endogenous serum albumin. This albumin conjugation extends the compound's plasma half-life from approximately 30 minutes (as seen with CJC-1295 No DAC) to approximately 8 days, enabling sustained GHRH receptor stimulation across extended experimental time frames.

Chemical and Molecular Data

The Drug Affinity Complex (DAC) Technology

The maleimide group in the MPA linker undergoes thiol-Michael addition with the free thiol of Cys-34 on albumin, the only free (non-disulphide-bonded) cysteine in serum albumin. This covalent bond is stable under physiological conditions. The resulting albumin-peptide conjugate inherits albumin's long half-life through two mechanisms: its large size (above 66 kDa) prevents glomerular filtration, and the neonatal Fc receptor (FcRn)-mediated albumin recycling pathway continuously rescues the conjugate from lysosomal degradation.

This DAC technology achieves covalent albumin binding, distinct from the non-covalent fatty-acid-based albumin binding used in Retatrutide and semaglutide, which rely on hydrophobic interactions.

Sustained vs Pulsatile GHRHR Activation

The fundamental pharmacodynamic distinction between the two CJC-1295 variants is the temporal pattern of GHRH receptor stimulation.

Pulsatile pattern (No DAC version). Discrete GH pulses following each administration, mimicking physiological GH secretion dynamics. Useful for studying pulse-dependent GH biology.

Sustained pattern (With DAC version). Maintained GHRHR activation across days, producing more constant lower-amplitude GH elevation. Enables investigation of tonic GH axis stimulation, receptor regulation, and long-duration IGF-1 responses.

Research has examined whether sustained versus pulsatile GHRHR stimulation produces qualitatively different downstream effects on IGF-1 production, body composition in animal models, and GH receptor expression. This remains an active area of GH axis pharmacology research.

Combined Research with GHS-R1a Agonists

CJC-1295 (With DAC) is frequently studied alongside Ipamorelin (GHS-R1a agonist), a complementary synergistic target. This dual-receptor approach allows investigation of synergistic GH release, and whether long-duration GHRHR activation combined with GHS-R1a agonism produces different outcomes than either compound alone.

Research Applications

CJC-1295 (With DAC) is used in long-acting GHRH analogue pharmacokinetic studies, sustained GH axis stimulation in chronic animal model experiments, comparison with CJC-1295 (No DAC) (pulsatile vs sustained paradigm), GH receptor regulation and desensitisation research, albumin-binding peptide pharmacology as a model system, and IGF-1 axis long-duration studies.

Storage and Handling

Store at -20 degrees C in a desiccated environment, protected from light. Reconstitute with bacteriostatic water. For in vitro studies where albumin binding is not desired, use serum-free medium with freshly reconstituted peptide, as albumin binding occurs rapidly in serum-containing media. Avoid repeated freeze-thaw cycles.

DAC Technology vs Other Half-Life Extension Strategies

Frequently Asked Questions

What happens to the DAC linker in serum-containing media during in vitro experiments?
When CJC-1295 (With DAC) is added to cell culture media containing serum (which contains albumin), the maleimide group immediately reacts with free thiols — primarily Cys-34 of albumin. This means that in standard serum-containing cell culture conditions, CJC-1295 (With DAC) rapidly becomes albumin-conjugated and its free peptide concentration falls dramatically. For in vitro studies where the unconjugated peptide's direct receptor binding is being studied, researchers should use serum-free media and freshly reconstituted peptide, or use the No DAC variant which remains as a free peptide in solution.

Can the sustained GH elevation from CJC-1295 (With DAC) cause receptor desensitisation?
Sustained receptor stimulation is a key research question for the With DAC variant. GHRHRs, like most GPCRs, can undergo desensitisation through beta-arrestin recruitment and receptor internalisation following prolonged agonist exposure. Research has examined whether the sustained GHRHR stimulation from the With DAC version leads to measurable receptor downregulation or functional desensitisation compared to the pulsatile stimulation from the No DAC version. This pharmacodynamic difference between the two variants is itself a subject of ongoing research interest.

Why does CJC-1295 (With DAC) still produce pulsatile GH despite its long half-life?
This counterintuitive finding — that pulsatile GH secretion persists even with sustained GHRHR stimulation — reflects the fundamental pacemaker role of somatostatin in regulating GH pulsatility. GH pulses are determined by the cyclic release of somatostatin from hypothalamic neurons, which periodically suppresses pituitary GH release regardless of GHRHR occupancy. Even with continuous GHRHR stimulation, when somatostatin tone is low, a GH pulse occurs; when somatostatin rises, GH release is suppressed. The published observation that GH pulsatility persists with CJC-1295 treatment has been important in understanding the hypothalamic pacemaker control of GH secretion.

For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.

Related research peptides: CJC-1295 (No DAC) | Ipamorelin | Retatrutide

View CJC-1295 (With DAC) product page